Clinical Trial Update: Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity [Phase 1]

View source ↗

Summary

An open-label Phase 1 study of regorafenib evaluated cardiovascular safety, tolerability, and anti-tumor activity in cancer patients and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Bayer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED